Connection Between Hypothyroidism, SIBO Risk, and Duodenal Microbiome Alterations

Overview

This study demonstrates an increased prevalence and risk of small intestinal bacterial overgrowth (SIBO) in individuals with hypothyroidism, particularly autoimmune thyroiditis. Treatment with levothyroxine appears to reduce this risk. Additionally, distinct alterations in the duodenal microbiome, including specific Gram-negative coliforms, are associated with hypothyroidism and SIBO status.

Background

Hypothyroidism is a common endocrine disorder characterized by low thyroid hormone levels and elevated TSH, often caused by autoimmune thyroiditis. It affects multiple organ systems and is more prevalent in women. Small intestinal bacterial overgrowth (SIBO) involves excessive bacteria in the small intestine, leading to gastrointestinal symptoms and is diagnosed by bacterial counts or breath testing. Previous studies suggest an association between hypothyroidism and SIBO, possibly due to decreased gut motility and altered gut microbiota. The REIMAGINE study investigates small bowel microbiome changes directly via duodenal aspirates, providing insights into the microbial alterations linked to hypothyroidism and SIBO.

Data Highlights

Key Findings

• SIBO prevalence was significantly higher in hypothyroid subjects (32.65%) compared to controls (15.17%) in the REIMAGINE cohort.
• Ten-year cumulative incidence of SIBO was increased in hypothyroidism of unspecified etiology (RR=2.20) and autoimmune thyroiditis (RR=2.40) compared to matched controls.
• Levothyroxine treatment was associated with a marked reduction in SIBO risk in both hypothyroidism (RR=0.33) and autoimmune thyroiditis (RR=0.78) groups.
• The duodenal microbiome in hypothyroid subjects included Neisseria as part of the core microbiome, absent in nonhypothyroid subjects.
• Gram-negative coliforms were increased in SIBO+ groups; Escherichia/Shigella predominated in nonhypothyroid SIBO+, whereas Klebsiella species were prevalent in hypothyroid SIBO+ subjects.
• These microbial alterations suggest a mechanistic link between hypothyroidism, SIBO development, and specific small bowel bacterial populations.

Clinical Implications

Clinicians should be aware of the increased risk of SIBO in patients with hypothyroidism, especially those with autoimmune thyroiditis. Monitoring for gastrointestinal symptoms and considering evaluation for SIBO may be warranted. Levothyroxine therapy not only treats hypothyroidism but may also reduce the risk of developing SIBO, highlighting the importance of adequate thyroid hormone replacement. Understanding specific microbial alterations could guide future targeted therapies.

Conclusion

Hypothyroidism is associated with an increased risk of SIBO and distinct alterations in the duodenal microbiome, which may be mitigated by levothyroxine treatment. These findings enhance understanding of the gut-thyroid axis and support integrated management approaches.

References

1. REIMAGINE Study Authors/2024 -- Connection Between Hypothyroidism, Small Intestinal Bacterial Overgrowth Risk, and Alterations in the Duodenal Microbiome